378 results on '"F, Severi"'
Search Results
2. Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer
- Author
-
Butt, J. Jenab, M. Willhauck-Fleckenstein, M. Michel, A. Pawlita, M. Kyrø, C. Tjønneland, A. Boutron-Ruault, M.-C. Carbonnel, F. Severi, G. Kaaks, R. Kühn, T. Boeing, H. Trichopoulou, A. la Vecchia, C. Karakatsani, A. Panico, S. Tumino, R. Agnoli, C. Palli, D. Sacerdote, C. Bueno-de-Mesquita, H.B. Weiderpass, E. Sánchez, M.-J. Bonet Bonet, C. Huerta, J.M. Ardanaz, E. Bradbury, K. Gunter, M. Murphy, N. Freisling, H. Riboli, E. Tsilidis, K. Aune, D. Waterboer, T. Hughes, D.J.
- Subjects
digestive system diseases - Abstract
The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case–control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04–1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44–3.27). In this prospective nested case–control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification. © 2018 UICC
- Published
- 2018
3. 327. Radioembolization with Yttrium-90 Microspheres in Hepatocellular Carcinoma: Initial Experience
- Author
-
S. Pasetto, A. Massella, F. Severi, M. Salgarello, V. Clementi, A. Masotto, E. Oliboni, and G. Taddei
- Subjects
0301 basic medicine ,Gastrointestinal tract ,Lung ,Tare weight ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Biophysics ,General Physics and Astronomy ,General Medicine ,Liver transplantation ,medicine.disease ,Scintigraphy ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Yttrium-90 microspheres ,medicine ,Radiology, Nuclear Medicine and imaging ,business ,Nuclear medicine ,Perfusion - Abstract
Purpose We present our initial experience on transarterial radioembolization (TARE) with Yttrium-90 glass microspheres in Hepatocellular Carcinoma (HCC) patients. The first objective was to choose the procedure for defining the dose to be delivered to the patient and a first evaluation of its effectiveness. Methods From January 2016 to October 2017, 18 consecutive patients (M = 17, F = 1, median age 73 [24–85] years) with HCC were selected. TARE was performed using 90Y glass microspheres [1] . The administration activity was defined by the MIRD method based on the uptake volume [2] . Lung and gastrointestinal tract shunts were evaluated two weeks before the TARE, by a diagnostic angiography and, respectively, scintigraphy and SPECT/CT, after hepatic perfusion with 99mTc macroaggregated albumin (MAA). 90Y dose was personalized based on the 99mTc MAA SPECT/CT dose distribution. The mean dosimetric parameters are: Lesion Volume (cm3) 144, Target/Uptake Dose (Gy) 216, Target Volume (cm3) 371, Liver Treated (%) 25, Lung Shunt (%) 7, Non Tumoral Liver Dose (Gy) 6, Total Activity Administered (GBq) 1.6. Response evaluation was performed in 17 patients. Results Complete response occurred in 9 patients, partial response in 5 patients, while progression was seen in 3 patients. During a median clinical follow-up of 8 (3–18) months, 6 patients died. Median disease free survival and overall survival were respectively 13 and 16 months. One patient led to down-staging, allowing liver transplantation. Conclusions The dose definition procedure adopted proved to be effective, in the reduced number of cases treated. More data need to be acquired to confirm this preliminary result.
- Published
- 2018
4. 324. FDG-PET texture analysis in NSCLC: Metabolic-pathological correlations
- Author
-
S. Pasetto, V. Clementi, M. Salgarello, Andrea Viti, and F. Severi
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lymphovascular invasion ,business.industry ,Biophysics ,General Physics and Astronomy ,General Medicine ,Pet imaging ,Open source software ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,business ,Pathological ,Lymph node - Abstract
Purpose in surgically resectable NSCLC prognosis is strongly affected by local invasiveness as well as unexpected lymph node diffusion found at surgery. Recently, texture analysis of PET imaging has emerged as a powerful tool to better define the metabolic behavior of neoplasms. The study is meant to evaluate the relationship of texture analysis features of surgically resected NSCLC with local invasiveness and regional sublicnical diffusion. Methods The study is a retrospective evaluation of prospectively collected data. We performed a 3D texture analysis of the PET scans on previously delineated lesion VOIs of resected stage Ia IIb NSCLC. The extraction of a list of texture analysis features was performed by an open source software package CGITA developed by Yu-Hua Dean Fang et al. [1] . We then evaluated their relationship with lymphovascular invasion, nodal upstaging and disease-free survival. Results tumours with lymphovascular invasion displayed higher levels of SUVmax, SUV entropy, normalized entropy, SUV standard deviation; and lower level of the following: normalized homogeneity, normalized inverse different moment (IDM). Tumors with nodal upstaging displayed higher levels of the following: SUV max, SUV entropy, normalized entropy, SUV standard deviation; and lower level of the following: normalized heterogeneity and normalized IDM. ROC analysis ruled out a stronger predictive power of texture analysis indicators when compared to SUVmax. Conclusions given its relationship with important prognostic indicators, texture analysis may provide a stratification of highly aggressive tumours from the very beginning of patient’s diagnostic path.
- Published
- 2018
5. Night work and health related quality of lifr: a study on nurses
- Author
-
Nicola Nante, Agnese Verzuri, M. F. Severi, Gabriele Messina, G. Bugnoli, V. Turchi, and A. M. Gentile
- Subjects
medicine.medical_specialty ,Nursing ,business.industry ,Family medicine ,media_common.quotation_subject ,Public Health, Environmental and Occupational Health ,Medicine ,Health related ,Leukemia inhibitory factor receptor ,Quality (business) ,business ,Night work ,media_common - Published
- 2015
6. P.09.19 RADIOEMBOLIZATION WITH YTTRIUM-90 MICROSPHERES IN HEPATOCELLULAR CARCINOMA: AN ITALIAN EXPERIENCE
- Author
-
E. Oliboni, G. Taddei, A. Massella, Massimo Cirillo, Matteo Salgarello, Giovanni Carbognin, P. Bocus, F. Severi, and A. Masotto
- Subjects
Hepatology ,business.industry ,Hepatocellular carcinoma ,Yttrium-90 microspheres ,Gastroenterology ,medicine ,medicine.disease ,business ,Nuclear medicine - Published
- 2018
7. 18F-sodium fluoride (18F-NaF) PET/CT scan for the assessment of brain metastases (BMs)
- Author
-
G. Gorgoni, S. Pasetto, V. Picece, F. Marchetti, F. Severi, Alessandro Inno, Matteo Salgarello, R. Magarotto, Simone Gori, Filippo Alongi, Massimo Cirillo, L Romano, P. Cassandrini, Alessandra Modena, Maurizio Nicodemo, R Casolino, Gianluigi Lunardi, M. Turazza, G Carbognin, and Maria Rosaria Valerio
- Subjects
chemistry.chemical_compound ,medicine.medical_specialty ,PET-CT ,Oncology ,chemistry ,business.industry ,Sodium fluoride ,Medicine ,Hematology ,Radiology ,Nuclear medicine ,business - Published
- 2017
8. Fetal sacrococcygeal teratoma
- Author
-
CV, Bellieni, primary, F, Molinaro, additional, M, Sica, additional, R, Angotti, additional, M, Messina, additional, C, Bocchi, additional, F, Severi, additional, and S, Carbone, additional
- Published
- 2017
- Full Text
- View/download PDF
9. Management of Puberty in Constitutional Delay of Growth and Puberty
- Author
-
Jesús Argente, W. Oostdijk, C. De Sanctis, F. Wu, P.G. Voorhoeve, G Trifiro, S. Di Maio, H.A. Delemarre-Van de Waal, Luciano Cavallo, F. De Luca, E. Crowne, E. Norjavaara, G. Tonini, and F. Severi
- Subjects
Male ,Peak bone mass ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Short stature ,Endocrinology ,medicine ,Humans ,Child ,Gonadal Steroid Hormones ,Growth Disorders ,Testosterone ,Puberty, Delayed ,business.industry ,Puberty ,Oxandrolone ,Body Height ,Regimen ,Sex steroid ,Pediatrics, Perinatology and Child Health ,Social relationship ,Female ,medicine.symptom ,business ,Hypogonadotrophic hypogonadism ,medicine.drug - Abstract
Constitutional delay of growth and puberty (CDGP) is the most common presenting form of short stature, but no single test can infallibly discriminate CDGP and isolated hypogonado- trophic hypogonadism. Management of puberty in CDGP aims to optimise not only growth - maintaining body proportions and improving peak bone mass without impairing growth potential - but also well-being; for example, the distress boys often suffer because of their lack of growth and pubertal progression can affect their school performance and social relationships. Typical sex steroid treatments to induce puberty in boys with CDGP include testosterone (T) enanthate, T undecanoate, mixed T esters, T transdermal patches, and oxandrolone p.o. Compared with other regimens, short-course low-dose depot T i.m. is an effective, practical, safe, well tolerated, and inexpensive regimen. Some unresolved problems in management include optimal timing and dose of sex steroid treatment, the role of GH in CDGP, and the management of CDGP in girls.
- Published
- 2001
10. Unresolved Problems in Optimal Therapy of Pubertal Disorders in Oncological and Bone Marrow Transplanted Patients
- Author
-
Assunta Albanese, A. Cicognani, E.C. Crowne, G. E. Butler, A. C S Hokken-Koelega, V. De Sanctis, Valentino Cherubini, E. Di Battista, Luciano Cavallo, F. Severi, M. Caruso-Nicoletti, Margherita Bozzola, B. Wonke, and Pediatrics
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Growth hormone deficiency ,Endocrinology ,Neoplasms ,medicine ,Humans ,Endocrine system ,Child ,Growth Disorders ,Bone Marrow Transplantation ,Chemotherapy ,Radiotherapy ,business.industry ,Puberty ,Brain ,Total body irradiation ,medicine.disease ,Combined Modality Therapy ,Optimal management ,Growth hormone treatment ,Radiation therapy ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Female ,Bone marrow ,Radiology ,business - Abstract
Specialised clinics for the long-term follow-up of survivors from childhood cancer have developed over recent years. The problems encountered among patients who received multiple chemotherapy and radiotherapy can be challenging and require high expertise and close collaboration among different professionals (e.g. oncologists, endocrinologists, radiotherapists, psychologists). Endocrine disorders are often seen, particularly among those who received cranial radiotherapy or gonadotoxic chemotherapy; puberty can be affected and the spectrum of disorders may range from precocious or accelerated puberty to delayed, arrested or even absent pubertal development. Growth impairment can be multifactorial and growth hormone deficiency is an important but probably not the only factor involved. Many questions remain about the optimal management of this group of young patients. In the consensus guidelines that follow the overview an attempt is made to help optimise patients’ growth and puberty by suggesting practical clinical approaches to some of the most challenging issues.
- Published
- 2001
11. A 200-Ms/s 10-mW switched-capacitor filter in 0.5-/spl mu/m CMOS technology
- Author
-
F. Severi, R. Castello, and A. Baschirotto
- Subjects
Engineering ,Total harmonic distortion ,Settling time ,business.industry ,Amplifier ,Slew rate ,Switched capacitor ,law.invention ,Capacitor ,law ,Filter (video) ,Operational amplifier ,Electronic engineering ,Electrical and Electronic Engineering ,business - Abstract
Wideband amplifiers with low but precisely known dc gain allow the achievement of accurate infinite impulse response switched-capacitor (SC) filters operating at very high sampling frequencies. The low and precise opamp gain value is taken into account while sizing the capacitors (precise opamp gain (FOG) approach), so that no idle phase is required for amplitude error compensation and double-sampling technique can be implemented. In a 0.5-/spl mu/m standard CMOS technology with 3.3-V power supply, an opamp is designed which exhibits a settling time of about 3 ns (for 0.1% settling accuracy) in a closed-loop configuration with input, feedback, and load capacitors of 0.5 pF, white the slew rate is 1 V/ns. The open-loop dc gain of the amplifier is set to the value of 80 (38 dB) by a gain-control closed loop, which guarantees an accuracy of /spl plusmn/2%. The proposed solution is validated by experimental results from a 200-Ms/s SC filter. From a single 3.3-V supply the filter consumes 10 mW (excluding clock generation) and exhibits a -40 dB total harmonic distortion for a 2-V/sub pp/ signal amplitude at 4 MHz, achieving a 62-dB dynamic range.
- Published
- 2000
12. Synthesis and activity of a new series of chalcones as aldose reductase inhibitors
- Author
-
Stefania Benvenuti, Luciano Antolini, Luca Costantino, Michele Melegari, F. Severi, and G. Vampa
- Subjects
Pharmacology ,chemistry.chemical_classification ,Aldose reductase ,Chalcone ,biology ,chalcones ,Sorbitol dehydrogenase ,Chemistry ,Organic Chemistry ,Glutathione reductase ,aldose reductase inhibitors ,General Medicine ,chemistry.chemical_compound ,sorbitol pathway ,X-ray analysis ,Polyol pathway ,Enzyme ,Biochemistry ,Enzyme inhibitor ,Drug Discovery ,biology.protein ,Aldehyde Reductase - Abstract
A new series of chalcone derivatives has been synthesized and tested in vitro in order to assess their ability to inhibit aldose reductase enzyme (ALR2) and their specificity towards the target enzyme with respect to other oxidoreductases, such as aldehyde reductase, sorbitol dehydrogenase, and glutathione reductase. All the compounds display affinity for ALR2. The X-ray crystal structure of 1-(2,4-dihydroxyphenyl)-3-(2-methoxyphenyl)propen-1-one was determined.
- Published
- 1998
13. Gamma Knife Radiosurgery in Skull Base Meningiomas
- Author
-
Antonio Nicolato, Alberto Pasqualin, F. Severi, P. Ferraresi, Roberto Foroni, Massimo Gerosa, E. Piovan, and B. Masotto
- Subjects
business.industry ,Gamma knife radiosurgery ,Gamma knife ,medicine.disease ,Meningioma ,Skull ,medicine.anatomical_structure ,otorhinolaryngologic diseases ,Medicine ,Surgery ,Neurology (clinical) ,business ,Nuclear medicine ,Base (exponentiation) - Abstract
Gamma Knife radiosurgery was performed on 50 patients (10 males and 40 females) with skull base meningiomas (SBMs) between February 1993 and September 1995. The patients ranged in age from 25 to 78 ye
- Published
- 1996
14. Teorema di Riemann-Roch e questioni connesse : Lectures given at a Summer School of the Centro Internazionale Matematico Estivo (C.I.M.E.) held in Varenna (Como), Italy, June 29-July 8, 1955
- Author
-
F. Severi and F. Severi
- Subjects
- Algebraic geometry
- Abstract
B.L. van der Waerden: Démonstration algébrique du théorème de Riemann-Roch.- F. Severi: Del teorema di Riemann-Roch per curve, superficie e varietà. Le origini storiche e lo stato attuale.- F. Hirzebruch: Arithmetic genera and the theorem of Riemann-Roch.
- Published
- 2011
15. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments
- Author
-
Franco Antoniazzi, G. Nizzoli, A Corrias, M Bozzola, S. Bernasconi, F. De Luca, F. Severi, C. de Sanctis, L. Tatò, M. Cisternino, G Chiumello, F. Rigon, and Giorgio Zamboni
- Subjects
medicine.medical_specialty ,Puberty, Precocious ,Buserelin ,Group A ,Group B ,Internal medicine ,medicine ,Humans ,Precocious puberty ,Child ,Administration, Intranasal ,Triptorelin Pamoate ,business.industry ,Bone age ,General Medicine ,Luteinizing Hormone ,medicine.disease ,Triptorelin ,Body Height ,Endocrinology ,Delayed-Action Preparations ,Pediatrics, Perinatology and Child Health ,Bone maturation ,Female ,Follicle Stimulating Hormone ,business ,Hormone ,medicine.drug - Abstract
In order to evaluate the effects of two long-acting luteinizing hormone-releasing hormone agonists on growth, bone maturation and final height in girls with central precocious puberty, we analyzed growth data from 40 girls (15 treated with buserelin intranasal spray (group A), 15 treated with triptorelin depot im every 28 days (group B) and 10 untreated (group C)). Patients in group A started treatment when chronological age (CA) was 7.7 +/- 0.9 years, bone age (BA) was 10.2 +/- 1.1 years and height was 131.9 +/- 5.0 cm. Patients in group B started therapy when CA was 7.6 +/- 0.5 years, BA 9.8 +/- 1.0 years and height 133.2 +/- 7.6 cm. The diagnosis of untreated patients (group C) was made when CA was 7.2 +/- 0.9 years, BA 9.6 +/- 2.2 years and height 130.2 +/- 8.6 cm. Both luteinizing hormone-releasing hormone agonists appeared to control precocious puberty. Final height in group B (160.6 +/- 5.7 cm) was significantly higher than that of group A (153.2 +/- 5.0 cm: p < 0.05) and group C (149.6 +/- 6.3; p < 0.01), whereas the difference between groups A and C was not statistically significant. In group B a positive difference was observed between final height (160.6 +/- 5.7 cm) and target height (157.6 +/- 5.9 cm) (ns); on the contrary, in groups A and C, final height was lower than target height (155.5 +/- 5.3 and 156.4 +/- 1.3 cm, respectively), but only in group C the difference was statistically significant (p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
16. FDG-PET/CT as a predictor of pathological complete response (pCR) in breast cancer (BC) patients (pts) treated with neoadjuvant chemotherapy (NAC): a single center retrospective study
- Author
-
S. Duranti, Filippo Alongi, Maria Rosaria Valerio, F. Severi, A. Fiorentino, Stefania Gori, M. Turazza, Alberto Massocco, A. Russo, Matteo Salgarello, G. Gorgoni, S. Pasetto, Alessandro Inno, Giuseppe Bogina, Gianluigi Lunardi, F. Marchetti, and Laura Bortesi
- Subjects
Oncology ,Chemotherapy ,medicine.medical_specialty ,PET-CT ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,Hematology ,medicine.disease ,Single Center ,Breast cancer ,Internal medicine ,medicine ,business ,Pathological ,Complete response - Published
- 2015
17. Teorema di Riemann-Roch e questioni connesse
- Author
-
F. Severi
- Published
- 2011
18. ChemInform Abstract: Synthesis, Characterization, and Crystallographic Analysis of Some Benzimidazole Derivatives
- Author
-
G. Vampa, F. Severi, L. Malmusi, Stefania Benvenuti, and Luciano Antolini
- Subjects
Benzimidazole ,chemistry.chemical_compound ,chemistry ,Stereochemistry ,General Medicine ,Combinatorial chemistry ,Characterization (materials science) - Published
- 2010
19. ChemInform Abstract: Synthesis, Antimicrobial and Genotoxic Properties of Some Benzoimidazole Derivatives
- Author
-
Stefania Benvenuti, Luciano Antolini, P. Mazza, Michele Melegari, Franca Zani, F. Severi, G. Vampa, and A. Saccetti
- Subjects
Chemistry ,Organic chemistry ,General Medicine ,Antimicrobial ,Combinatorial chemistry - Published
- 2010
20. ChemInform Abstract: Synthesis and Activity of a New Series of Chalcones as Aldose Reductase Inhibitors
- Author
-
F. Severi, G. Vampa, Luca Constantino, Stefania Benvenuti, Michele Melegari, and Luciano Antolini
- Subjects
Aldose reductase ,Stereochemistry ,Chemistry ,Organic chemistry ,General Medicine - Published
- 2010
21. Contents, Vol. 36, 1991
- Author
-
M. Zachmann, C. Jung-Hoffmann, Mikihiko Kudo, Jean-Marie Cottet-Emard, Carlos Dieguez, D. Gambarana, R. Rappaport, T. Ohzeki, Kiyohiko Kato, A. D’Alberton, Kenji Ohyama, Jens Christoffersen, Felipe F. Casanueva, M. Cisternino, Rosa Bussi, R. Keret, G. Giorgiani, Makoto Nakazono, Andrea Giustina, Jose I. Vidal, Fernando Cordido, F. Locatelli, A. Valtorta, F. Severi, C. Gübelin-De Campo, A. Silbergeld, M. Bozzola, Aino Torsson, Hajime Watanobe, M. Ballabio, Meta Damkjœr Nielsen, Masanori Ohta, M. Fitzner, Z. Laron, René Mornex, Masatoshi Fujimoto, Merete Jørgensen, M. Nissim, M. Lapidot, D. Bochicchio, Kazuo Takebe, B. Manella, Rumiko Aoki, Grazia Buffoli, M. Wasserman, I. Ashkenazi, Katharina M. Main, Ieuan A. Hughes, G. Faglia, Knud E. Petersen, Yoshiko Nakagomi, R. Orefice, G. Giorda, Remo Pagliari, William B. Wehrenberg, B. Schindel, Jørn Müller, Niels E. Skakkebæk, H. Kuhl, A.G. Harros, Malou Philips, Niels E. Skakkebœk, Liliane Peyrin, A. Moretta, and Toshitsugu Yamori
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism - Published
- 1991
22. Caratteristiche epidemiologiche e cliniche del diabete mellito insulino-dipendente in bambini italiani di età inferiore a tre anni Epidemiological and clinical characteristics of type I insulin dependent diabetes mellitus in Italian children under 3 years old
- Author
-
F. CERUTTI, F. CHIARELLI, E. CACCIARI, S. SALARDI, V. CHERUBINI, E. BARTOLOTTA, G. CHIUMELLO, F. MESCHI, M. COTELLESSA M. MAZZELLA, F. DAMMACCO, F. FREZZA, G. DE GIORGI, M. SPOSITO, A. FALORNI, F. FARAONI, M. POCECCO, S. MARINONI, C. SACCHETTI, G. AGOSTA, I. RABBONE, F. SEVERI, R. LORINI, G. STOPPOLONI, S. TUMINI, A. VERROTTI, M. VANELLI, S. CANTONI, IAFUSCO, Dario, F., Cerutti, F., Chiarelli, E., Cacciari, S., Salardi, V., Cherubini, E., Bartolotta, G., Chiumello, F., Meschi, M. COTELLESSA M., Mazzella, F., Dammacco, F., Frezza, G., DE GIORGI, M., Sposito, A., Falorni, F., Faraoni, M., Pocecco, S., Marinoni, C., Sacchetti, G., Agosta, I., Rabbone, F., Severi, R., Lorini, G., Stoppoloni, Iafusco, Dario, S., Tumini, A., Verrotti, M., Vanelli, and S., Cantoni
- Published
- 1995
23. [Quality in drug administration: review of the therapeutic information system during hospitalization]
- Author
-
F, Severi
- Subjects
Drug Therapy ,Drug-Related Side Effects and Adverse Reactions ,Quality Assurance, Health Care ,Clinical Pharmacy Information Systems ,Humans ,Medication Errors ,Professional Staff Committees - Abstract
The mistakes taking place in therapy administration are regarded as indicative elements of a bad work quality. In order to avoid them and to get the best obtainable quality, the Arezzo USL Administration has established a Work Group charged to ascertain the possible errors and to review the different methods enforced inside the informations therapeutic system. An experimentation has been carried out in sixteen hospital wards, with a subsequent control of the results. In all the U.U.O.O. of Arezzo the "Thermography with direct control" system has been adopted, as it has proved to succeed in eliminating a great deal of the possible risks.
- Published
- 1999
24. A 200Ms/s 10mW switched-capacitor filter in 0.5µm CMOS technology
- Author
-
F. Severi, R. Castello, A. Baschirotto, Severi, F, Baschirotto, A, and Castello, R
- Subjects
Engineering ,high-frequency SC filter ,Hardware_PERFORMANCEANDRELIABILITY ,closed-loop gain-control circuit ,witched-capacitor filter ,law.invention ,rail-to-rail output swing ,witched capacitor filter ,law ,0.5 micron ,CMOS analogue integrated circuit ,Hardware_INTEGRATEDCIRCUITS ,Electronic engineering ,Active filter ,operational amplifier ,active filter ,business.industry ,3 V ,closed loop system ,opamp gain ,Swing ,capacitor sizing ,Switched capacitor ,CMOS technology ,Sizing ,high-bandwidth op amp ,circuit feedback ,Capacitor ,CMOS ,10 mW ,Operational amplifier ,business ,Voltage ,output dc-voltage - Abstract
Precise opamp gain (POG) design allows high-frequency SC filters using high-bandwidth op amps with low but precisely-known dc-gain, whose value is used as a parameter in the capacitor sizing. Using an op amp dc-gain Ao with a maximum relative deviation /spl epsi/, this concept allows the same performance accuracy obtained with standard design using an opamp with dc gain Ao//spl epsi/. In this work, using a standard 0.5/spl mu/m CMOS technology and 5V supply, 150MSample/s is achieved, consuming 20mW. The CMOS opamp dc-gain is set with a closed-loop gain-control circuit. In addition, the output dc-voltage is fixed by a CMOS circuit. This results in dc output voltage independent of technological variations, enabling rail-to-rail output swing.
- Published
- 1999
25. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy
- Author
-
A, Barreca, M, Bozzola, A, Cesarone, P H, Steenbergh, P E, Holthuizen, F, Severi, G, Giordano, and F, Minuto
- Subjects
Insulin-Like Growth Factor Binding Protein 1 ,Male ,Human Growth Hormone ,Insulin-Like Growth Factor II ,Humans ,Infant ,Promoter Regions, Genetic ,Polymerase Chain Reaction ,Body Height ,Growth Disorders - Abstract
We report a case of short stature associated with high circulating levels of insulin-like growth factor (IGF)-binding protein-1 (IGFBP-10 and low levels of IGF-II responsive to pharmacological treatment with GH. Our patient suffered severe growth failure from birth (2.06 SD below the mean for normal full-term boys, and 5.2 and 7.3 SD below the mean at 5 and 10 months). Studies carried out before referral to our pediatric unit included normal 46,XY karyotype and normal encephalic imaging. Other endocrine and metabolic alterations and other systemic diseases were excluded. At 1.7 yr of age (length, 6.1 SD; weight, 4.6 SD; head circumference, 1.4 SD below the mean, respectively) the patient was referred to our pediatric unit. The baseline GH concentration was 31 microg/L, and the peak after an arginine load was 59.6 microg/L. In the same samples GH bioactivity was nearly superimposable (RIA/Nb2 bioactivity ratio = 0.9). Fasting insulin and glucose concentrations were 7.4 microU/mL and 65 mg/dL, respectively, both normally responsive to an oral glucose load. GH insensitivity was excluded by a basal IGF-I concentration (64 ng/mL) in the normal range for 0- to 5-yr-old boys and its increase after 2 IU/day hGH administration for 4 days. IGFBP-3 (0.5 microg/mL) was slightly reduced, whereas IGFBP-1 (2218 and 1515 ng/mL in two different basal samples) was well above the normal values for age and was suppressible by GH (maximum suppression, -77% at 84 h) and glucose load (maximum suppression, -46% at 150 min). The basal IGF-II concentration was below the normal range (86 ng/mL), whereas IGFBP-2 was normal (258 ng/mL). Analysis of the promoter region of IGFBP-1 and IGF-II failed to find major alterations. Neutral gel filtration of serum showed that almost all IGF-I activity was in the 35- to 45-kDa complex, coincident with IGFBP-1 peak, while the 150-kDa complex was absent, although the acid-labile subunit was normally represented. At 2.86 yr (height, 65.8 cm; height SD score, -7.3; height velocity SD score, -5) the patient underwent treatment with 7 IU/week human GH; after 4 months, the patient's height was 68.5 cm (height SD score, -6.9) corresponding to a growth velocity of 8.3 cm/yr (0.3 height velocity SD score). IGFBP-1 was reduced (216 ng/mL), although still in the high range, whereas IGF-I (71 ng/mL), IGFBP-3 (0.62 microg/mL), and IGF-II (111 ng/mL) were only slightly increased. The IGF-I profile showed activity in the 150-kDa region. In conclusion, we speculate that the increased IGFBP-1 values found in this patient produce 1) inhibition of IGF-I biological activity and, therefore, a resistance to IGF-I not due to a receptor defect for this hormone; 2) inhibition of formation of the circulating 150-kDa ternary complex and, therefore, an accelerated clearance rate of IGF peptides; 3) inhibition of the feedback action on GH, leading to increased GH levels, which could suggest the diagnosis of GH insensitivity syndrome; and 4) inhibition of body growth.
- Published
- 1998
26. Exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation and evidence for CYP21B gene point mutations in true precocious puberty
- Author
-
M, Cisternino, E, Dondi, M, Martinetti, R, Lorini, L, Salvaneschi, M, Cuccia, and F, Severi
- Subjects
Heterozygote ,HLA-A Antigens ,17-alpha-Hydroxyprogesterone ,Histocompatibility Testing ,Infant ,Puberty, Precocious ,Blotting, Southern ,HLA-B14 Antigen ,Adrenocorticotropic Hormone ,HLA-B Antigens ,Child, Preschool ,Humans ,Point Mutation ,Regression Analysis ,Female ,Adrenal Cortex Function Tests ,Steroid 21-Hydroxylase ,Child - Abstract
Following the observation of two patients affected by true precocious puberty who went on to develop polycystic ovary syndrome (PCOS) and who were found to be heterozygotes (carriers) for 21-hydroxylase deficiency (21-OHD), we decided to evaluate the frequency of heterozygosity for adrenal 21-OHD in patients with true precocious puberty.We investigated 32 girls affected by true precocious puberty, by the single-dose ACTH stimulation test, HLA typing and the molecular analysis of the CYP21B gene encoding for the 21-OH enzyme, in order to detect gene deletions or point mutations. Twenty-eight cases were on LHRH analogue treatment and the remaining four, untreated owing to parental refusal, were investigated 0.5-1.5 years after spontaneous menarche.After ACTH testing, 13 out of the 32 (41%) cases displayed higher 17-hydroxyprogesterone (17-OHP) levels than normal but less than those found in patients affected by nonclassical adrenal hyperplasia (CAH); these levels were similar to those observed in obligate heterozygotes for CAH due to 21-hydroxylase deficiency (21-OHD). HLA typing showed a significantly increased frequency of the HLA alleles A28 and B14 which are peculiar to the HLA haplotypes of nonclassical CAH due to 21-OHD. Molecular analysis of the CYP21B gene showed that in four out of the 10 tested patients with an exaggerated 17-OHP response there were heterozygous point mutations of the CYP21B gene. In contrast, no CYP21B gene abnormalities were detected in the eight tested patients with normal 17-OHP. No differences were found between carriers and non-carriers of the 21-OHD with regard to age at onset of precocious puberty, clinical features, bone age acceleration and gonadal suppression induced by LH-RH analogue treatment. Two out of the four untreated patients who were investigated after menarche were found to be carriers of the 21-OHD; these girls showed signs of androgen excess, irregular menses and polycystic ovaries.A high frequency of heterozygosity for adrenal steroid 21-OHD was found in our patients with true precocious puberty. This adrenal defect does not seem to influence the pattern of central precocious puberty, but these patients require long-term follow-up as they might go on to develop polycystic ovary syndrome (PCOS). Whether or not heterozygosity of the 21-OHD may be related to the premature activation of the hypothalamo-pituitary-gonodal axis remains to be defined.
- Published
- 1998
27. Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives
- Author
-
Michele Melegari, G. Vampa, Stefania Benvenuti, Luca Costantino, and F. Severi
- Subjects
chemistry.chemical_classification ,Aldose reductase ,biology ,Stereochemistry ,Pharmaceutical Science ,aldose reductase inhibitors ,Inhibitory postsynaptic potential ,Chemical synthesis ,Amino acid ,Acylation ,benzoyl-L-amino acid derivatives ,Enzyme ,Biochemistry ,chemistry ,Enzyme inhibitor ,Aldehyde Reductase ,Drug Discovery ,Lens, Crystalline ,biology.protein ,Animals ,Cattle ,Amino Acids ,Enzyme Inhibitors - Abstract
A series of N-(4-methoxy, 4-fluoro, 4-trifluoromethyl and 4-nitrobenzoyl)-L-amino acids was synthesized and their inhibitory activity towards bovine lens aldose reductase (ALR2) was tested.
- Published
- 1998
28. Insulin-like growth factors (IGF-I and IGF-II) and IGF-binding protein-3 production by fibroblasts of patients with Turner's syndrome in culture
- Author
-
A, Barreca, D, Larizza, G, Damonte, M, Arvigo, P, Ponzani, A, Cesarone, F, Lo Curto, F, Severi, G, Giordano, and F, Minuto
- Subjects
Adult ,Male ,Adolescent ,Estradiol ,Human Growth Hormone ,Turner Syndrome ,Fibroblasts ,Blotting, Northern ,Drug Combinations ,Insulin-Like Growth Factor Binding Protein 3 ,Insulin-Like Growth Factor II ,Child, Preschool ,Humans ,Female ,RNA, Messenger ,Insulin-Like Growth Factor I ,Child ,Cells, Cultured ,Skin - Abstract
Reports indicate that in plasma insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are normal in patients with Turner's syndrome (TS). The aim of our study was to evaluate both the spontaneous and the stimulated synthesis of these peptides by mesenchymal cells obtained from skin biopsies of patients affected with TS. We compared the ability of fibroblasts from six TS patients with that of fibroblasts from six age-matched control (C) subjects to synthesize in vitro IGF-I, IGF-II, and IGFBP-3 under basal and GH-, estradiol (E2)-, or GH- plus E2-stimulated conditions. Furthermore, we evaluated IGF-I, IGF-II, and IGFBP-3 messenger ribonucleic acid (mRNA) expression in fibroblasts from TS and C subjects. Fibroblasts obtained from TS patients release into the medium significantly lower amounts of IGF-I and IGF-II than C fibroblasts (P = 0.0435 and 0.0318, respectively). In TS fibroblasts, GH and E2 are able to induce a similar increase, although not significant, of IGF-I secretion into the medium (163 +/- 75% and 112 +/- 41% of control values). On the contrary, in C fibroblasts, GH is more effective (275 +/- 61%; P = 0.0277) than E2 (75 +/- 46%). In both cell lines, GH and E2 do not significantly modify IGF-II release. Interestingly, the medium conditioned by fibroblasts from TS contains, under basal conditions, significantly higher amounts (273 +/- 79 ng/1 x 10(6) cells) of IGFBP-3 than that from control fibroblasts (67 +/- 19 ng/1 x 10(6) cells; P = 0.0191). GH exerts a stimulatory effect, although it is not statistically significant, on IGFBP-3 secretion, particularly in control fibroblasts. By contrast, the effect of E2 is inhibitory in all TS fibroblast cell lines, although it does not reach statistical significance (P = 0.067). In agreement with these data, a reduced mRNA expression of the genes encoding for IGF peptides was evident in TS fibroblasts, whereas no significant difference could be demonstrated for IGFBP-3 mRNA. The results suggest a reduced autocrine/paracrine action of IGFs in TS and indicate that skin fibroblast cultures can give information on the local responsiveness to the treatment.
- Published
- 1997
29. Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children
- Author
-
F, Locatelli, R, Maccario, P, Comoli, F, Bertolini, G, Giorgiani, D, Montagna, F, Bonetti, P, De Stefano, G, Rondini, G, Sirchia, and F, Severi
- Subjects
Male ,Salvage Therapy ,Immunity, Cellular ,Time Factors ,Transplantation Conditioning ,Graft Survival ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Infant, Newborn ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Fetal Blood ,Lymphocyte Subsets ,Hematopoiesis ,Nuclear Family ,Antibody Formation ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Erythropoiesis ,Female ,Lymphocyte Count ,Child ,Bone Marrow Diseases ,Immunocompetence - Abstract
Matched related cord blood transplantation (CBT) has been successfully used to rescue patients undergoing myeloablative therapy. However, few data are available on the kinetics of hematological and immunological reconstitution of CBT recipients. We have investigated the hematological engraftment and immune recovery following related CBT in three patients, with acute lymphoblastic leukemia, aged 10, 9 and 7 years and with a body weight of 31, 40 and 25 kg, respectively. All patients engrafted and none experienced acute or chronic graft-versus-host disease. The time needed to achieve granulocyte recovery was 13, 26 and 29 days, respectively and platelet recovery occurred in 28, 49 and 51 days. All patients presented a marked increase of HbF, the values observed being much greater than those documented in patients given marrow transplantation and comparable with those observed in normal children in the first year of age. The recovery of T cell immunity, as well as that of natural killer subpopulations, mimicked that described in BMT recipients, a quicker return of CD8+ T cells determining the characteristic inversion of CD4/CD8 ratio. An impressive increase in the percentage and absolute number of B lymphocytes, apparently not related to viral infections, was demonstrable in all three cases. These data suggest that CBT recipients can experience a slight delay in hematological recovery when compared with patients given BMT. The reconstitution of erythropoiesis seems to recapitulate the ontogenetic pattern and the kinetics of recovery of the immune system reproduce that observed after BMT with the peculiarity of B cell expansion in peripheral blood.
- Published
- 1996
30. Gamma Knife radiosurgery in skull base meningiomas. Preliminary experience with 50 cases
- Author
-
A, Nicolato, P, Ferraresi, R, Foroni, A, Pasqualin, E, Piovan, F, Severi, B, Masotto, and M, Gerosa
- Subjects
Adult ,Male ,Meningeal Neoplasms ,Humans ,Female ,Middle Aged ,Meningioma ,Radiosurgery ,Skull Base Neoplasms ,Disease-Free Survival ,Aged ,Follow-Up Studies - Abstract
Gamma Knife radiosurgery was performed on 50 patients (10 males and 40 females) with skull base meningiomas (SBMs) between February 1993 and September 1995. The patients ranged in age from 25 to 78 years (mean age 56 years). The location of the tumors was anterior fossa (n = 4), sphenoorbital (n = 2), sellar region (n = 5), cavernous sinus (n = 26), petroclival (n = 12), and occipital foramen (n = 1). The tumor volume ranged from 0.6 to 20 cm3 (mean 8.6 cm3). The mean values for dose planning were edge isodose (EI) 46.7%, edge dose (ED) 18.0 Gy, maximum dose 39.8 Gy, average dose (AD) 25.4 Gy, and average number of isocentres 5.7. The patients were analyzed for five parameters: tumor volume (7.5 vs.or = 7.5 cm3); EI (50 vs.or = 50%); ED (18 vs.or = 18 Gy); AD (25 vs.or = 25 Gy), and primary versus residual or recurrent tumors. The overall frequency of tumor growth control (TGC) was 98%, with 1- and 2-year TGC rates of 97% and 100%, respectively. The most favorable neurological results were obtained with a tumor volume7.5 cm3 (p0.05), EIor = 50% (NS), EDor = 18 Gy (NS) and with primary SBMs (p0.01). A favorable TGC was demonstrated at follow-up imaging examinations when the tumor volume wasor = 7.5 cm3 (100% TGC rate), EI50% (100%), EDor = 18 Gy (100%), AD25 Gy (100%), in both primary SBMs (100%) and residual or recurrent SBMs (96.5%). To date, only 3 (6%) of the 50 patients have presented signs of neurological worsening related to the Gamma Knife radiosurgery. While no early complications were noted, neuroradiological follow-up did show delayed transient imaging complications (3 edema and 1 radionecrosis; 8% of all patients). In conclusion, our preliminary results seem to confirm that Gamma Knife radiosurgery is an effective and safe adjuvant or a feasible alternative primary treatment in controlling or preventing SBM progression.
- Published
- 1996
31. Gamma Knife radiosurgery for intracranial metastases: from local tumor control to increased survival
- Author
-
Roberto Foroni, F. Severi, Antonio Nicolato, Albino Bricolo, P. Ferraresi, E. Piovan, Massimo Gerosa, B. Masotto, A. Pasoli, and G. Barone
- Subjects
Adult ,Male ,medicine.medical_specialty ,business.industry ,Brain Neoplasms ,medicine.medical_treatment ,Gamma knife radiosurgery ,Gamma knife ,Middle Aged ,Tumor control ,Radiosurgery ,humanities ,Survival Rate ,medicine ,Quality of Life ,Humans ,Surgery ,Female ,Neurology (clinical) ,Radiology ,business ,Nuclear medicine ,Aged ,Retrospective Studies - Abstract
We have analyzed a series of 225 patients with intracranial metastases (343 lesions), treated in our department by Gamma Knife radiosurgery over a 30-month period. We have used a modified Pittsburgh protocol and performed 242 procedures on 164 single/78 multiple lesions. Primary tumors were mostly carcinomas of the lung (52%) and breast (11.6%). Neuroradiological localization of the target was usually performed by stereotactic computed tomography. Magnetic resonance imaging was only used in special circumstances. Routine dose planning was assisted by three-dimensional reconstruction programs. Mean tumor volume was larger than expected (5.7 ml). Mean prescription dose and average dose were 21.1 and 29.9 Gy, respectively. Middle- and long-term results were evaluated in a subset of 152 patients (236 lesions) with adequate (4 months) follow-up. Mean follow-up was 53.1 weeks with 61/152 patients still living. There was a predominance of retrospectively classified 'not fully eligible cases' among the survivors, mainly because of uncontrolled primary tumor. The 1-year local tumor control rate was 88.2%. Treatment-related radiological (3.9%) and clinical (1.6%) sequelae were minimal. Overall mean survival in these patients (40 weeks) turned out to be higher than that commonly reported after conventional surgical-radiation treatments. It was encouraging that the mean survival of 'fully' eligible patients was 51 weeks. Karnofsky performance status and neurological (Order Grading) performance scores were consistently high for most of the follow-up period. Functional Independence and the Palliative Index were not far from the value of mean survival. The main cause of death remains uncontrolled systemic disease (64.8%). On the other hand, the relative incidence of intracranial tumor progression was considerably decreased. This indicated that these patients should perhaps be treated more aggressively and underlines the need for randomized trials to determine the optimal treatment.
- Published
- 1996
32. Hyperinsulinemia in children and adolescents after bone marrow transplantation
- Author
-
R, Lorini, L, Cortona, A, Scaramuzza, P, De Stefano, F, Locatelli, F, Bonetti, and F, Severi
- Subjects
Blood Glucose ,Male ,Adolescent ,Islets of Langerhans ,Hypothyroidism ,Antineoplastic Combined Chemotherapy Protocols ,Insulin Secretion ,Humans ,Insulin ,Prospective Studies ,Child ,Radiation Injuries ,Autoantibodies ,Bone Marrow Transplantation ,Glycated Hemoglobin ,Leukemia ,C-Peptide ,Hypogonadism ,Lymphoma, Non-Hodgkin ,Anemia, Aplastic ,Glucagon ,Child, Preschool ,Growth Hormone ,Female ,Insulin Resistance ,Radioisotope Teletherapy ,Whole-Body Irradiation - Abstract
We report 34 patients (aged 5-18 years) with acute (n = 26) or chronic (n = 1) leukemia, non-Hodgkin's lymphoma (n = 3) or severe aplastic anemia (n = 4) evaluated for pancreatic beta-cell function 9 months to 10.2 years after autologous (n = 19) or allogeneic (n = 15) BMT. Before BMT, all patients received cytotoxic drugs, combined with total body irradiation (TBI) in 24 cases or thoracoabdominal irradiation (TAI) in 4 children. Patients were investigated for fasting blood glucose (FBG), HbA1C, anti-insulin (IAA) and islet cell antibodies (ICA), first-phase insulin response (FPIR) and insulinemia/glycemia (I/G) ratio on i.v. glucose tolerance test (GTT) and C-peptide response after glucagon 1 mg i.v. Results were compared with those obtained in 21 age- and sex-matched controls. None of the patients or controls had IAA and/or ICA. FBG and HbA1C were normal in all children. In the patients, glycemia on i.v. GTT was similar to controls whereas insulin levels I/G ratio and FPIR were significantly higher in patients than in controls, as well as C-peptide levels. We divided the patients on the basis of the radiotherapy into group I with TBI (n = 18), group II with TAI (n = 4) and group III who were not irradiated (n = 4). The I/G ratio, FPIR on i.v. GTT and C-peptide response were significantly higher in group I compared with the other two groups and controls. The increased insulin and C-peptide levels in our patients with normal glycemia might be interpreted as a state of insulin resistance, more evident in patients who received TBL.
- Published
- 1995
33. Myelodysplastic syndromes: the pediatric point of view
- Author
-
F, Locatelli, M, Zecca, A, Pession, E, Maserati, P, De Stefano, and F, Severi
- Subjects
Male ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Myelodysplastic Syndromes ,Humans ,Female ,Child - Abstract
Myelodysplastic syndromes (MDS) are clonal disorders of the multipotent hematopoietic stem cell characterized by ineffective hematopoiesis and associated with marrow hypercellularity, increased intramedullary cell death and peripheral cytopenias of varying severity. Patients with myelodysplasia have a propensity (20% to 30% of cases) to undergo transformation into acute myeloid leukemia (AML), and a large body of evidence indicates that MDS represent steps in the multiphasic evolution of AML. Progression of the disease is characterized by expansion of the abnormal clone and inhibition of normal hematopoiesis leading to deterioration of the blood cell count and/or development of AML. MDS are relatively unusual in childhood, representing only 3% of pediatric hematological malignancies, although it has been reported that up to 17% of pediatric AML cases may have a previous myelodysplastic phase. The first systematic attempt at morphological classification of MDS was provided by the French-American-British (FAB) group. However, the FAB classification of MDS is only partially applicable in children. Some variants are extremely rare or absent (refractory anemia with ring sideroblasts and chronic myelomonocytic leukemia), and other peculiar pediatric disorders, represented by juvenile chronic myelogenous leukemia (JCML) and the monosomy 7 syndrome, are not included. Moreover, since there is a partial overlap between pediatric MDS and myeloproliferative disorders and the variants occurring in young children have rather specific features, some confusion still surrounds the nosographical definition of childhood MDS, so that none of the proposed classifications are widely accepted and used. Characteristically, some genetic conditions such as Fanconi's anemia, Shwachman's and Down's syndromes predispose to the development of MDS in childhood. The most common variants of childhood MDS are represented by JCML and the monosomy 7 syndrome, both disorders typically occurring in young children. JCML is characterized by a spontaneous growth of granulocyte-macrophage progenitors that show a striking hypersensitivity to granulocyte-macrophage colony-stimulating factor. Clinical presentation resembles that of some myeloproliferative disorders, with massive organomegaly usually not observed in the classically reported variants of MDS. Clinical features of the monosomy 7 syndrome resemble those observed in JCML and a differential diagnosis between these two entities relies upon the higher percentage of fetal hemoglobin, the more pronounced decrease in platelet count and, in some cases, the lack of the peculiar cytogenetic abnormality in the latter. With the number of children being cured of cancer constantly rising, a significant increase in secondary or chemotherapy-related myelodysplasia is being observed, and these disorders represent a formidable challenge for pediatric hematologists due to their poor response to chemotherapy.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1995
34. Synthesis, characterization, crystallographic analysis, antifungal and genotoxic properties of some 1-methyl-1H-imidazoles
- Author
-
P. Mazza, Stefania Benvenuti, L. Malmusi, G. Vampa, Luciano Antolini, Franca Zani, and F. Severi
- Subjects
Pharmacology ,chemistry.chemical_classification ,biology ,Stereochemistry ,Organic Chemistry ,Nitro compound ,Sulfoxide ,General Medicine ,Bacillus subtilis ,biology.organism_classification ,antifungal genotoxic properties 1-methyl-1H-imidazoles ,Chemical synthesis ,Synthesis, crystallographic analysis, antifungal genotoxic properties 1-methyl-1H-imidazoles ,Sulfone ,chemistry.chemical_compound ,Synthesis ,chemistry ,Drug Discovery ,Microsome ,Imidazole ,Growth inhibition ,crystallographic analysis - Abstract
Summary A number of 1-methyl-1 H -imidazole derivatives and some of their oxygenated products were synthesized. An HPTLC technique for following the oxidation reactions in the different experimental conditions used was applied. The X-ray crystal structures of 1-methyl-2-methylsulfanyl-5-nitro-1 H -imidazole, 2-methanesulfinyl-1-methyl-5-nitro-1 H -imidazole and 2-methanesulfonyl-1-methyl-5-nitro-1 H -imidazole were determined. The compounds obtained were investigated for antimycotic and genotoxic activities. The compounds tested were found to exert very low growth inhibition against yeasts and moulds. Moderate antifungal properties against dermatophytes were demonstrated for 5-nitro derivatives. 2-Methanesulfonyl-1-methyl-5-nitro-1 H -imidazole was the most active substance. All 5-nitroimidazoles were genotoxic in Bacillus subtilis rec -assay, Salmonella microsome test and in Saccharomyces cerevisiae mitotic segregation assay. Structure-activity relationships are discussed.
- Published
- 1995
35. SYNTHESIS, CHARACTERIZATION, AND CRYSTALLOGRAPHIC ANALYSIS OF SOME BENZOIMIDAZOLE DERIVATIVES
- Author
-
F. Severi, Stefania Benvenuti, Luciano Antolini, L. Malmusi, and G. Vampa
- Subjects
Diffraction ,Chemistry ,Hydrogen bond ,SYNTHESIS, CHARACTERIZATION, CRYSTALLOGRAPHIC BENZOIMIDAZOLE DERIVATIVES ,Organic Chemistry ,SYNTHESIS ,Molecular conformation ,Characterization (materials science) ,Crystal ,Crystallography ,Intramolecular force ,Molecule ,CRYSTALLOGRAPHIC BENZOIMIDAZOLE DERIVATIVES ,CHARACTERIZATION - Abstract
A number of benzenesulfonyl derivatives of benzoimidazol-2-ylamine and 1-methyl-benzoimidazol-2-ylamine were synthesized, their synthesis reactions under different experimental conditions being monitored by hptlc. The crystal and molecular structures of N-(1-benzenesulfonyl-1,3-dihydrobenzoimidazol-2-ylidene)benzenesulfonamide (4) and N-(1-benzenesulfonyl-3-methyl-1,3-dihydro-benzoimidazol-2-ylidene)-benzenesulfonamide (7) were determined by X-ray diffraction analysis. The structure of compound 4 is made up of two crystallographically independent molecules and that of compound 7 of one molecule. In both cases, the structure contains the imido form of the molecules. There are strong conjugative effects between the imido groups and the imidazolic rings. Weak intramolecular CH···O hydrogen bonding interactions could influence the molecular conformations.
- Published
- 1995
36. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants
- Author
-
F, Locatelli, M, Zecca, P, Pedrazzoli, L, Prete, S, Quaglini, P, Comoli, P, De Stefano, Y, Beguin, G, Robustelli della Cuna, and F, Severi
- Subjects
Leukemia ,Cost-Benefit Analysis ,Graft Survival ,Anemia ,Transplantation, Autologous ,Recombinant Proteins ,Treatment Outcome ,Acute Disease ,Humans ,Immunologic Factors ,Transplantation, Homologous ,Blood Transfusion ,Erythropoiesis ,Child ,Erythropoietin ,Bone Marrow Transplantation - Abstract
We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) in children undergoing allogeneic or mafosfamide-purged autologous BMT for ALL or AML. rHuEPO was administered intravenously at a dose of 75 U/kg/day for 30 days after transplant. Ten rHuEPO-treated patients receiving allogeneic BMT and 10 given autologous BMT were compared with 15 allogeneic and 10 autologous historical controls. Endogenous EPO production was appropriate for the degree of anemia after autologous BMT. In these patients, rHuEPO did not accelerate erythroid repopulation and did not modify transfusion requirements. With allogeneic BMT, erythroid marrow activity increased faster in patients given rHuEPO than in controls and resulted in higher red cell production, the mean reticulocyte count on day +30 being 187 +/- 51 x 10(9)/l in treated patients versus 107 +/- 63 x 10(9)/l in controls (p0.01). The total number of RBC units administered was 1.7 +/- 1.3 in the rHuEPO group versus 5.1 +/- 3.0 in the control group (p0.001). The total number of platelet transfusions was 4.0 +/- 2.3 for patients given allogeneic BMT and receiving rHuEPO versus 8.4 +/- 6.8 for historical controls (p0.05) whereas it was similar in rHuEPO-treated and control autologous BMT patients.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
37. Immunodeficiency, growth hormone deficiency and central nervous system involvement in a girl
- Author
-
M, Maghnie, V, Monafo, G L, Marseglia, A, Valtorta, A, Avanzini, A, Moretta, U, Balottin, J L, Touraine, and F, Severi
- Subjects
Brain Diseases ,Growth Hormone ,Immunologic Deficiency Syndromes ,Humans ,Female ,Child - Abstract
We describe a mentally retarded 12-year-old girl with ataxia in whom diagnostic evaluation for short stature revealed isolated growth hormone (GH) deficiency and multiple central nervous system (CNS) lesions. Assessment of immunologic status, performed because of the persistence of recurrent respiratory tract infections, showed associated deficiencies of IgG2-IgG4 and specific antibody response; in addition, in vitro lymphocyte response to mitogens was low, in vitro production of interleukin-2 and of IgM was absent, and natural killer activity was decreased. The possibility that association of the CNS lesions, GH deficiency and immune defects could be due to alterations of the neuro-immuno-endocrine network secondary to a disturbance of neurotransmitters induced by precocious CNS damage of a viral or ischemic nature is discussed.
- Published
- 1992
38. Influence of growth hormone-releasing hormone (GHRH) on phytohemagglutinin-induced lymphocyte activation: comparison of two synthetic forms. GHRH and PHA-induced lymphocyte activation
- Author
-
A, Valtorta, A, Moretta, R, Maccario, M, Bozzola, and F, Severi
- Subjects
Adult ,Humans ,Interleukin-2 ,Phytohemagglutinins ,Growth Hormone-Releasing Hormone ,Lymphocyte Activation ,Sermorelin ,Peptide Fragments - Abstract
The in vitro effect of synthetic human growth hormone-releasing hormone (GHRH) on mitogen-induced lymphocyte proliferation and lymphokine secretion was investigated. Peripheral blood mononuclear cells (PBMC) of healthy adults were incubated in the presence and absence of increasing concentrations (from 0.006 to 50 micrograms/ml) of two forms of GHRH differing in amino-acid sequence (GHRH 1-44 and GHRH 1-29) or of increasing concentrations (from 0.0012 to 20 U/ml) of recombinant human insulin (rh-insulin). Low concentrations of GHRH 1-29 increased phytoemoagglutinin (PHA)-induced lymphoproliferation, while high concentrations inhibited lymphocyte response, interleukin-2 (IL-2) secretion and IL-2 receptor expression on activated cells. A toxic effect was excluded since no differences in cell viability were observed between cells cultured with and without hormone. GHRH 1-44 did not affect PHA-induced lymphoproliferation, IL-2 production and IL-2 receptor expression. Low concentrations of rh-insulin increased PHA-elicited lymphoproliferation, while high concentrations did not decrease lymphocyte response. The present study suggests that GHRH modulates in vitro human T lymphocyte functions.
- Published
- 1991
39. Recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) in cyclic neutropenia
- Author
-
F, Locatelli, P, Pedrazzoli, M, Zecca, R, Maccario, G, Giorgiani, L, Prete, L, Nespoli, and F, Severi
- Subjects
Male ,Leukocyte Count ,Neutropenia ,Fever ,Recurrence ,Granulocyte-Macrophage Colony-Stimulating Factor ,Humans ,Immunologic Factors ,Peritonitis ,Child ,Recombinant Proteins - Abstract
We describe the case of a 12-year-old boy affected by cyclic neutropenia, at high risk of developing life-threatening infections, treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The drug was effective in reducing the severity of neutropenia and infectious complications in our patient. It was administered for brief periods of time, in contrast to the daily continuous administration reported for rHuG-CSF. Therefore, more extensive studies must be performed to identify the most effective time schedule for the drug. In vitro studies of hemopoietic progenitor cells were useful, in this case, to predict treatment response.
- Published
- 1991
40. Pubertal development after bone marrow transplantation in adolescents
- Author
-
M, Cisternino, M, Bozzola, F, Locatelli, N, Lahlou, D, Gambarana, P, Manfredi, G, Giorgiani, C, Milicia, M, Roger, and F, Severi
- Subjects
Male ,Adolescent ,Estradiol ,Ovary ,Puberty ,Humans ,Antineoplastic Agents ,Female ,Child ,Whole-Body Irradiation ,Bone Marrow Transplantation - Published
- 1991
41. Gonadal function in adolescents receiving different conditioning regimens for bone marrow transplantation
- Author
-
G, Giorgiani, M, Bozzola, M, Cisternino, F, Locatelli, D, Gambarana, F, Bonetti, M, Zecca, R, Lorini, and F, Severi
- Subjects
Adolescent ,Ovary ,Humans ,Female ,Primary Ovarian Insufficiency ,Child ,Busulfan ,Cyclophosphamide ,Whole-Body Irradiation ,Bone Marrow Transplantation - Published
- 1991
42. Familial haemophagocytic lymphohistiocytosis treated with allogeneic bone marrow transplantation
- Author
-
L, Nespoli, F, Locatelli, F, Bonetti, F, Porta, M, Zecca, A, Gibardi, D, Gambarana, V, Vitale, G R, Burgio, and F, Severi
- Subjects
Male ,Histiocytosis, Non-Langerhans-Cell ,HLA Antigens ,Histocompatibility ,Humans ,Infant ,Transplantation, Homologous ,Female ,Hematopoietic Stem Cells ,Bone Marrow Transplantation - Published
- 1991
43. Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development
- Author
-
P. Marradi, Luciano Tatò, M. Pierson, B. Dousset, Mariangela Cisternino, D. Sommelet, F. Severi, Mauro Bozzola, Franco Antoniazzi, and B. P. Leheup
- Subjects
Adult ,Male ,Delayed puberty ,endocrine system ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,pubertal development ,hormone releasing hormone injection ,Growth Hormone-Releasing Hormone ,Chorionic Gonadotropin ,Injections ,Gonadotropin-Releasing Hormone ,Endocrinology ,Internal medicine ,medicine ,Humans ,Testosterone ,Child ,business.industry ,Insulin ,Puberty ,thalassemia major ,Growth hormone–releasing hormone ,Androgen ,Growth hormone secretion ,Growth Hormone ,Thalassemia ,Female ,medicine.symptom ,Gonadotropin ,Sleep ,business ,hormones, hormone substitutes, and hormone antagonists ,Hormone - Abstract
Thirty-five patients with thalassemia major, aged 7 to 21 years, were studied to define the relationship between the pubertal development and the growth-hormone (GH) secretion during sleep, after administration of GH-releasing factor (hpGRF 1-44), and betaxolol-glucagon or arginin- insulin. Pubertal development was classified as being appropriate or delayed for chronological age. GH response to pharmacological stimuli and during sleep was not linked to the pubertal development according to the chronological age. The peak of GH secretion after GHRH injection was significantly delayed in thalassemic patients with retarded puberty. The integrated secretion of GH during the 120-min test was slightly but not significantly reduced in these patients. The prepubertal pattern of GHRH response was restored in the patients receiving substitutive therapy by HCG or testosterone. The alteration of GH response to GHRH in thalassemic patients is likely to be only due to delayed puberty and decreased endogeneous GHRH secretion since it is corrected by androgen or gonadotropin replacement.
- Published
- 1991
44. [Bone marrow transplantation in the treatment of severe aplastic anemia]
- Author
-
F, Locatelli, M, Zecca, L, Nespoli, and F, Severi
- Subjects
Male ,Child, Preschool ,Anemia, Aplastic ,Humans ,Female ,Child ,Bone Marrow Transplantation - Abstract
Bone marrow transplantation (BMT) in patient affected by severe aplastic anemia (SAA), is successful in 70-80% of cases, when performed with HLA identical brother or syngeneic twin as donors, and in 11-45% of cases when performed from aploidentical-identical related or HLA identical unrelated donor. The different conditioning regimens (Cy alone or in combination with TBI) have shown similar results in the long term outcomes. Cyclosporin-A is very effective in avoiding rejection and controlling GVHD.
- Published
- 1991
45. Growth in pubertal children after bone marrow transplantation
- Author
-
M, Bozzola, F, Locatelli, M, Cisternino, D, Gambarana, G, Giorgiani, F, Bonetti, A, Valtorta, A, Moretta, R, Lorini, and F, Severi
- Subjects
Male ,Child, Preschool ,Growth Hormone ,Brain ,Humans ,Female ,Child ,Growth Disorders ,Bone Marrow Transplantation - Published
- 1991
46. Prospective study of endocrine side-effects following bone marrow transplantation in childhood
- Author
-
M, Bozzola, F, Locatelli, M, Cisternino, F, Bonetti, D, Gambarana, G, Giorgiani, M, Zecca, P, De Stefano, R, Lorini, and F, Severi
- Subjects
Male ,Islets of Langerhans ,Endocrine Glands ,Puberty ,Humans ,Autoimmunity ,Female ,Growth ,Prospective Studies ,Child ,Bone Marrow Transplantation - Published
- 1991
47. Relapsing eruptive psoriasis and immunological changes triggered by growth hormone therapy in a growth hormone-deficient girl
- Author
-
F Severi, Giacomo Rabbiosi, Renata Lorini, M. A. Girani, D Larizza, Mohamad Maghnie, and Giovanni Borroni
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,media_common.quotation_subject ,Dermatology ,Growth hormone ,Pathogenesis ,Recurrence ,Psoriasis ,Internal medicine ,medicine ,Humans ,Girl ,Child ,Growth Disorders ,media_common ,Chemotherapy ,business.industry ,medicine.disease ,Endocrinology ,Concomitant ,Growth Hormone ,Toxicity ,Chronic Disease ,Gh treatment ,Female ,Drug Eruptions ,business - Abstract
A 9.8-year-old girl with growth hormone (GH) deficiency and concomitant chronic and localized psoriasis of the groins and axillae showed repeated and sudden relapse of eruptive psoriasis after GH treatment. The aggravating effect of GH and the improvement of the skin condition after withdrawal suggests, at least in this case, that GH plays a significant role in the pathogenesis of psoriasis.
- Published
- 1990
48. Subject Index Vol. 66, Suppl. 1, 1996
- Author
-
G. Pendl, A. Pasoli, Zheng-qing Hu, W.Y. Chung, K.A. Leber, L. Widén, C.M. Duma, X. Wu, L. Kihlström, G. Pencil, S. Kawamoto, C.B. Chasan, Y.J. Lim, K. Takakura, M. Rossato, T. Tsuzuki, K. Suzuki, A.A. Kemeny, O. Major, S. Takai, M. Hirato, A. Nieoullon, S. Nakayama, H. Oyama, J. Hirato, J.C. Flickinger, T. Sakaki, M.M.H. Teng, V.P. Collins, A.H. Morice, I. Lax, R. Nicoletti, J. Russell, H.K. Inoue, Y. Andou, T. Kawamata, M. Rigotti, A. Bricolo, B. Masotto, S. Fukuoka, Y. Sasaki, S. Goetsch, T.D. Nichols, Y. Seo, Y.L. Lee, H. Sato, T. Hardy, Gene H. Barnett, S. Nakamura, S. Tsunoda, W. Leem, R. Sartori, J.A. Fiedler, W.P. Gwan, N. Konishi, D.M.C. Forster, M. Vial, M. Söderman, T. Kobayashi, G. Marchini, S. Babighian, C. Lindquist, M. Dal Sasso, S. Stone-Elander, Y. Umebara, F. Severi, Bin-Jiang Wang, M. Izawa, Jia-Zhong Dai, W.Y. Guo, M. Habeck, S. Takahashi, A. Pasqualin, P. Ferraresi, Y. Kwon, M. Ide, G. Barone, L. Manera, D.E. Schwartz, Xing-Rong Chen, W.R. Hudgins, A. Posewitz, S.J. Goetsch, Y. Hiasa, A. Benati, J. Nakagawara, Y. Imahori, S.S. Vermeulen, Y. Ohmori, E. Yoshino, J.C. Peragut, O. Chinot, C. Ohye, G.M. Friehs, M. Hayashi, R. Foroni, L.D. Lunsford, J. Jakubowski, L.K. Kerkerian-Legoff, B. Karlsson, A. Hampshire, Y. Kida, J. Mogard, O. Levrier, H.C. Pan, T. Yamaki, H. Tung, E. Kato, J. Régis, J. Plombon, J.L. Barker, Liang-fu Zhou, Zi-wei Gao, Y. Aoki, H. Fujino, S. Eustacchio, G. Norén, P. Grimm, H. Kohga, A. Lizarraras, E. Piovan, P. Farnarier, L. Bonomi, S. Hagiwara, H.J. Landy, S. Matsubara, M. Rey, M. Jimbo, D. Kondziolka, J.C. Ganz, J. Nakamura, J.Y. Ting, A. Nicolato, T. Tanaka, R.F. Young, M. Tago, K. Kitz, L.W. Wang, C.Y. Chang, C.J. Whang, Li Pan, J. Peragut, A.M. Markoe, T. Shibazaki, H. Nagano, C. Scharfen, K. Suematsu, R. Aigner, E. Maurincomme, A. Terahara, Ren-He Dong, D. Porcheron, T. Hirai, M. Nakamura, M. Yamamoto, L. Walton, K. Nakagawa, S. Furuya, H. Kurita, Wei-ming Xu, S. Naruse, G.F. Fueger, T. Higuchi, W.C. Chu, Wei-min Xu, K. Ott, A. Zama, O. Schröttner, H. Hiyama, H. Inoue, S. Murayama, R. Marks, G.P. Urbani, S. Ueda, K. Tanohata, K. Ericson, D. Hodgens, K. Nakaya, M. Niwa, T. Mori, M.C. Wu, K. Arai, M. Gerosa, and M. Takanashi
- Subjects
Index (economics) ,business.industry ,Medicine ,Surgery ,Subject (documents) ,Neurology (clinical) ,business ,Neuroscience ,Clinical psychology - Published
- 1996
49. Subject Index, Vol. 36, 1991
- Author
-
A. Silbergeld, Hajime Watanobe, Masatoshi Fujimoto, M. Lapidot, A. Moretta, Toshitsugu Yamori, Fernando Cordido, Makoto Nakazono, M. Fitzner, F. Locatelli, Knud E. Petersen, Mikihiko Kudo, Jørn Müller, Carlos Dieguez, I. Ashkenazi, D. Gambarana, Yoshiko Nakagomi, R. Rappaport, T. Ohzeki, H. Kuhl, L. Peyrin, Katharina M. Main, C. Jung-Hoffmann, Niels E. Skakkebæk, Meta Damkjœr Nielsen, A. Valtorta, A.G. Harros, Jose I. Vidal, M. Nissim, D. Bochicchio, William B. Wehrenberg, A. D’Alberton, Felipe F. Casanueva, M. Cisternino, G. Giorgiani, Aino Torsson, Rosa Bussi, M. Zachmann, G. Faglia, Malou Philips, R. Orefice, M. Bozzola, G. Giorda, Remo Pagliari, Ieuan A. Hughes, M. Wasserman, Jean-Marie Cottet-Emard, Masanori Ohta, B. Manella, F. Severi, René Mornex, B. Schindel, Rumiko Aoki, Grazia Buffoli, Merete Jørgensen, C. Gübelin-De Campo, Kazuo Takebe, M. Ballabio, Z. Laron, R. Keret, Jens Christoffersen, Andrea Giustina, Kiyohiko Kato, Kenji Ohyama, and Niels E. Skakkebœk
- Subjects
Endocrinology ,Index (economics) ,Endocrinology, Diabetes and Metabolism ,Statistics ,Subject (documents) ,Mathematics - Published
- 1991
50. ANTI-RETROVIRUS ANTIBODIES IN INSULIN-DEPENDENT DIABETIC CHILDREN AT DIAGNOSIS AND DURING 1–2.6 YRS FOLLOW-UP
- Author
-
G. Achilli, F Severi, L Cortona, Pasquale Ferrante, R Lorini, E Cattaneo, and Andrea Scaramuzza
- Subjects
biology ,business.industry ,Nod ,Human leukocyte antigen ,biology.organism_classification ,medicine.disease ,Virology ,law.invention ,Pathogenesis ,Retrovirus ,Antigen ,law ,Diabetes mellitus ,Pediatrics, Perinatology and Child Health ,Immunology ,biology.protein ,Medicine ,Antibody ,business ,Polymerase chain reaction - Abstract
Viruses have long been implicated in the pathogenesis of insulin-dependent diabetes (IDDM). Recently it has been observed that β-cell specific expression of endogenous retrovirus is associated with the development of insulins and diabetes in non-obese diabetic (NOD) mice. The aim of our study was to evaluate the presence of retroviral markers in 27 newly diagnosed IDDM children, aged 9.6±3.8 yrs (range 3-15.9 yrs). In all patients anti-islet cell (ICA), anti-insulin (IAA), anti-thyroid (TgA and MsA) antibodies were evaluated and HLA typing was performed. Virological studies included the search for anti-retrovirus (HTLVs) antibodies using the western immunoblotting (WIB) and the HTLV-I DNA amplification by polymerase chain reaction (PCR) for tax/rex pol, and gag (PIS) regions. At onset of IDDM ICA were present in 19 patients (70%) and IAA in 2 of them, while all patients were negative for TgA and MsA. HTLVs antibodies were detected in 10 out of the 27 patients (37%) while no HTLV-I DNA sequencies were detected using our PCR assay. Interestingly, we have observed a frequent association between the presence of HTLVs antibodies and the presence of HLA-DR3 and DQ2 antigens. Until now, during 1-2.6 yrs follow-up we could revalue 13 children, four with HTLVs antibodies and 9 without antibodies. In 2/4 patients the HTLVs antibodies disappeared and in another boy, with five antibodies at onset of IDDM (directed against p 19, rgp21, p24, p26, p36) only one antibody (directed against rgp 21) was constantly present.
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.